Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Prior treatment

• Use of intravitreal complement inhibitors in study eye

Other illness

• Has active ocular disease that compromises or confounds visual function
• History of surgery for retinal detachment
• Has ocular condition other than GA secondary to AMD
• Active viral, bacterial or fungal infection
• History of choroidal neovascularization in the study eye

Other

• Has GA secondary to causes other than AMD
• Hereditary or acquired complement deficiency
• Liver injury as evidenced by abnormal liver function tests
• Donating blood

• Clinical diagnosis of GA of the macula secondary to AMD
• GA lesions between 2.5 and 12.5 mm2 at screening
• Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol
• Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol